Shire's first prescription eye drop, Xiidra 5% now available in the US

Xiidra is the only prescription eye drop approved by the FDA for the treatment of both signs and symptoms of dry eye disease.

"Shire worked rapidly to bring Xiidra to market following the approval of this new treatment - a first-in-its-class medication and the first prescription treatment to be approved for both the signs and symptoms of dry eye disease," said Perry Sternberg, Head, US Commercial. "We have a full range of modern, educational access programs to support the millions of patients across the US living with dry eye disease. This delivers on our commitment to showing up differently in ophthalmics."

"As the number of people presenting with the signs and symptoms of dry eye disease increases, the availability of a new prescription treatment option for this condition is an exciting development," Eric D. Donnenfeld, National Medical Director, TLC Laser Eye Centers. "We now have a new prescription eye drop that is specifically indicated for the signs and symptoms of dry eye disease, an often common eye condition that may be progressive."